TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Bed Rest Versus Moderate Activity in Preterm Premature Rupture of Membranes (PPROM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant~* Gestational age between 23 weeks 0 days - 32 weeks 0 days~* Diagnosed with preterm premature rupture of membranes~Exclusion Criteria:~* Cervical dilation greater than or equal to 3cm~* Active labor~* Evidence of infection~* Inability to provide informed consent~* Requirement for continuous fetal monitoring

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bedrest (Type: NO_INTERVENTION): Bedrest is a standard recommendation for patients with PPROM. Subjects randomized to this arm of the study will undergo the following:~1. Receive recommendation for bedrest (standard of care).~2. Have maternal mood and muscle strength evaluated on enrollment and after delivery (observational study procedure).~3. Wear a pedometer to measure activity when out of bed (observational study procedure).
- Moderate Activity (Type: EXPERIMENTAL): Subjects randomized to this arm of the study will undergo the following:~1. Receive recommendation to ambulate 150 feet, twice per day (interventional study procedure). Prior to each session of ambulation, an ultrasound will be performed to ensure adequate amniotic fluid volume and appropriate fetal position, and a fetal heart rate tracing will be obtained to ensure that there is reassuring fetal status (observational study procedure). During each session of ambulation, the fetal heart rate tracing will be monitored continuously (observational study procedure).~2. Have maternal mood and muscle strength evaluated on enrollment and after delivery (observational study procedure).~3. Wear a pedometer to measure activity when out of bed (observational study procedure).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Benefits of Relaxation by Music Therapy on PTSD Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* PTSD~Exclusion Criteria:~* neurological diseases~* addiction

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- musicotherapy (Type: EXPERIMENTAL): daily sessions of music listening during 2 months, associated with their standard treatment,
- waiting list (Type: NO_INTERVENTION): waiting list

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Combined Treatment of Prolonged Exposure and Pramipexole for Posttraumatic Stress Disorder and Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females between the ages of 18 and 60~2. Current DSM-V diagnosis of PTSD comorbid with MDD~3. CAPS-5 ≥ 25, and 17-item HRSD ≥ 17~4. Able to give consent, fluent in English~Exclusion Criteria:~1. Prior or current diagnosis with traumatic brain injury, bipolar disorder, psychotic disorder, gambling or impulse control disorders, or dementia~2. History of psychosis, psychotic disorder, mania or bipolar disorder~3. Severe substance use disorder excluding nicotine (i.e., nicotine use disorder and mild-moderate alcohol/cannabis use disorder are accepted)~4. Individuals at risk for suicide based on history and current mental state. BDI-II suicide item \> 2 or CGI-Severity baseline score of 7.~5. Treatment with antidepressants or other psychotropic medication in the past 4 weeks (or 6 weeks for fluoxetine; an exception will be made for zolpidem used intermittently for sleep).~6. Pregnancy or plans to become pregnant during the period of the study.~7. Current psychotherapy~8. Current unstable or untreated medical illness~9. Any condition that would exclude clinical MRI exam (e.g. pacemaker, paramagnetic metallic prosthesis, surgical clips, shrapnel, necessity for constant medicinal patch, some tattoos, severe obesity, claustrophobia)~10. History of untoward reaction to pramipexole

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- PE/Pramipexole (Type: EXPERIMENTAL): Experimental: Prolonged Exposure/Pramipexole Prolonged Exposure (PE) Therapy consists of 10 sessions of 90-minute duration, normally conducted once a week. In addition to receiving PE as described above, patients will have Pramipexole treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Role of Traditional Chinese Medicine in the Treatment of Chronic Childhood Immune Thrombocytopenia (ITP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Children (\< 18 years) diagnosed with chronic ITP; \>1 year after a first diagnosis and baseline platelet count \< 30,000. The diagnosis of ITP will be the responsibility of the Pediatric Hematology specialist in each participating center.~-~Exclusion Criteria:~1. Children with thrombocytopenia due to other causes. 2. Refusal of child or guardian to participate.~-

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Traditional Chinese Medicine (Type: EXPERIMENTAL): A traditional Chinese Medicine (TCM) therapist will diagnose and prescribe the herbal remedies according to TCM principles from one of four formulations or any combination of the four formulations, i.e. Bu Zhong Yi Qi Tang, Zhi Xue Tang, Chuan xin lian kang yan pian mod, Tian Wang Bu xin Dan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fertility Assessment in Patients With Klinefelter Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* males between the ages of 12 and 25~* diagnosed with mosaic or non-mosaic Klinefelter's Syndrome~* having bilaterally descended testes~* not having had a febrile illness within 3 months of enrollment.~Exclusion Criteria:~* previous treated with gonadotoxic chemotherapeutic or radiation regimen.~* psychological, psychiatric, or other conditions which prevent giving fully informed consent.

- Gender: MALE
- Minimum Age: 12 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.~Key Inclusion Criteria:~* Histologic diagnosis of unresectable stage III or IV metastatic melanoma~* Prior ipilimumab induction treatment (3 mg/kg)~* Documented disease control \[Stable Disease ≥3 months or Partial Response/Complete Response\] after ipilimumab induction~* Documented progressive disease following disease control~Key Exclusion Criteria:~* Patients with brain metastasis are excluded, unless they are free of neurologic symptoms related to metastatic brain lesions and do not receive systemic corticosteroid therapy for the purpose of reducing intracranial inflammation in the 10 days prior to beginning retreatment with ipilimumab~* Any intervening anticancer therapy between last dose of ipilimumab induction and ipilimumab retreatment on study~* Patients who experienced any grade 3 immune-related adverse event (irAE) (except for endocrinopathies where clinical symptoms were controlled with appropriate hormone replacement therapy) or any grade 4 toxicity during prior treatment with ipilimumab~* Patients with a prior irAE that has not improved to grade 1 or better at randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ipilimumab, 3 mg/kg (Type: EXPERIMENTAL): Participants received ipilimumab, 3 mg/kg, by intravenous infusion, every 3 weeks for a total of 4 doses or until disease progression, unacceptable toxicity, or withdrawal of consent
- Chemotherapy (Type: ACTIVE_COMPARATOR): Participants received the investigator's choice of chemotherapy, administered per package instructions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PUVA Versus PUVA + IFN Alpha 2a in Mycosis Fungoides

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Mycosis fungoides Stage Ia Ib IIa~* Written informed consent~* 18-70 y.o., both sex~* No concomitant systemic disease~Exclusion Criteria:~* Pregnant or lactating women~* Fertile women not accepting contraception~* Medical history of melanoma or non melanoma skin cancer~* Concomitant infections~* Immunodeficiency states~* Previous Heart disease~* Respiratory insufficiency~* Chronic RRenal insufficiency~* Chronic hepatopathy~* Epilepsy~* Depression~* Leucocytes \<3000 or neutrophiles \<1000 or thrombocytes \<100000 or hemoglobin \<12 gr/dL or ANA \<1/80~* Treatment with systemic steroids~* Altered thyroid hormones~* Previous resistance to PUVA and/or IFN~* Hypersensitivity to IFN~* Patients under treatment with teophiline and/or dicumarol~* Previous total skin electron beam~* Wash up period less than 3 month for IFN and /or PUVA~* Wash up period less than 1 month for topical treatments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): 8-MOP + UVA x 24 weeks
- B (Type: ACTIVE_COMPARATOR): IFN alone, 2 weeks, 8-MOP + UVA irradiation + IFN, 22 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Impact of Prostate Only Versus Pelvic Radiation for N+ Prostate Cancer.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histological proven carcinoma of the prostate~* Positive lymph nodes found on extended pelvic dissection (EPLND) defined as:~* Removal of the lymphatic tissue in the obturator fossa + along the external iliac vessels + additional complete resection of the lymph nodes (lnn) along, medially and laterally to, the hypogastric vessels~* If technically feasible: removal of lnn along the common iliac vessels~* Removal of ≥10 lnn~* Treatment of the primary tumor by either radical prostatectomy or EBRT~* Willing to receive androgen deprivation therapy~* World health organization 0-2~* Written informed consent~Exclusion Criteria:• \>4 positive lnn found on EPLND~* Prior pelvic irradiation~* Other primary tumor (except for non-melanoma skin tumors) diagnosed \<5 years before enrollment~* Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prostate(bed) only (Type: EXPERIMENTAL): external beam radiotherapy limited to the prostate(bed)
- Prostate(bed) and pelvis (Type: ACTIVE_COMPARATOR): external beam radiotherapy to the prostate(bed) and pelvic lymph node regions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Concurrent Chemoradiation Versus Surgery With Adjuvant Therapy in Advanced Laryngopharyngeal Cancers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with biopsy-proven, previously untreated, T3/T4 tumors (with focal cartilage erosion on computed tomography \[CT\] scan); squamous cell carcinoma of larynx and hypopharynx.~* Patients with Karnofsky Performance Scale (KPS) \> 80~* Patients must have resectable tumors which are potentially curable with conventional surgery and radiation therapy.~* Willing to participate in trial and get randomized~Exclusion Criteria:~* Gross cartilage invasion~* Extensive soft tissue infiltration~* Large nodal disease~* Distant metastases~* Synchronous primary

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Concurrent Chemoradiation
- 2 (Type: ACTIVE_COMPARATOR): Laryngectomy + adjuvant radiotherapy/chemoradiotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Side Effects of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) Directed Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who will start with an angiogenesis inhibitor or EGFR inhibitor~* Concomittant chemotherapy, immunotherapy or radiotherapy is allowed~* Age above 18 years at start of treatment~* Willingness to give written informed consent~Exclusion Criteria:~* Unable to give written informed consent~* Age under 18 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Observation (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Renal Nerve Stimulation and Renal Denervation in Patients With Sympathetic Ventricular Arrhythmias

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. The patient is willing and able to comply with the protocol and has provided written informed consent.~2. The patient falls within the target group as stated in 4.1.~3. Patient is an acceptable candidate for RDN treatment~4. Patient is 18-85 years of age~5. Documentation of ventricular arrhythmia (ECG, rhythm strip or ICD interrogation)~Exclusion Criteria:~1. Contraindication to anticoagulation therapy or heparin.~2. Previous selective cardiac sympathetic denervation or previous RDN procedure.~3. Acute coronary syndrome, cardiac surgery, PCI or stroke within 3 months prior to enrolment.~4. Untreated hypothyroidism or hyperthyroidism.~5. More than grade 1/3 valvular regurgitation and/or significant valve stenosis (moderate or severe).~6. Severe LV dysfunction (LVEF \<20% and/or grade 3/4 diastolic dysfunction).~7. Enrolment in another investigational drug or device study.~8. Woman currently pregnant or breastfeeding or not using reliable contraceptive measures during fertile age.~9. Mental or physical inability to participate in the study.~10. Planned cardiovascular intervention.~11. Life expectancy ≤ 12 months.~12. Renal artery stenosis \>50% of the arterial lumen, or renal artery lumen ≤3 mm.~13. Complex renal artery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- CPVT (Type: OTHER): catecholaminergic polymorphic ventricular tachycardia (CPVT) patients
- long QT syndrome (Type: OTHER): long QT syndrome patients
- ARVC (Type: OTHER): arrhythmogenic right ventricular cardiomyopathy (ARVC) patients
- HCM (Type: OTHER): hypertrophic cardiomyopathy (HCM) patients
- DCM (Type: OTHER): dilated non-ischemic cardiomyopathy (DCM) patients
- ICM (Type: OTHER): ischemic cardiomyopathy (ICM) patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: E-23596 - Use of NCPAP Cycling to Wean Preterm Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Preterm infants between 25-28 weeks gestation~* Ventilated for respiratory distress syndrome (RDS)~* Extubated to NCPAP for at least 72 hours.~Exclusion Criteria:~* Major congenital~* Chromosomal anomalies.

- Gender: ALL
- Minimum Age: 72 Hours
- Maximum Age: 75 Days
- Healthy Volunteers: f

Study Arms:
- Group A-NCPAP Cycling group (Type: EXPERIMENTAL): Infants in Group A were cycled between NCPAP and nasal prongs. For the first 12 hours, infants received 10 hours of NCPAP and 2 hours of 1 litre per minute of nasal prongs (NP). For the next 12 hours, infants received 8 hours of NCPAP and 4 hours of NP. In the subsequent 24 hours, infants alternated between 6 hours of NCPAP and 6 hours of NP. In the last 24 hours of intervention they alternated between 4 hours of NCPAP and 8 hours of NP.
- Group B-Continuous NCPAP (Type: ACTIVE_COMPARATOR): Infants randomized to group B received continuous NCPAP at a CPAP distending pressure of 4 cm of water for 72 hours. Both the groups after 72 hours of intervention were weaned to 1litre per minute NP. During the intervention period all infants were scored using the ACoRN respiratory score on a 12 hourly basis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Exercise and Pain Sensitivity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18 and 35 years~* Untrained (i.e. less than 2 hours of organised exercise per week in the last 6 months - physical activity related to transportation (e.g. bicycling) is not included)~* Generally healthy according a medical exam at screening, history~* Willing and able to participate in all measurements~* Willing and able to attend all training sessions~* Willing to keep the habitual activity and amount of training constant (ie screening activity and training volume).~* 20 ≤ body mass index (BMI) ≤ 28 kg/m2~* Speak, read and write Danish~Exclusion Criteria:~* Pregnant or breastfeeding~* Current or previous symptoms of autoimmune disease (eg, inflammatory bowel disease, multiple sclerosis, lupus, rheumatoid arthritis)~* Planned surgery during the study period~* Current or former musculoskeletal injuries or illnesses, including but not confined to:~* Ligament Injuries~* Meniscus Injuries~* Osteoarthritis~* Patellofemoral Pain Syndrome~* Backache~* Neck pain~* tendinopathy~* Current or past diagnosis, signs or symptoms of significant cardiovascular disease, including but not limited to:~* Ischemic heart disease~* Arteriosclerosis~* Medical conditions that contraindicate exercise, including but not limited to:~* Chronic or congenital heart disease~* Asthma~* Chronic Obstructive Pulmonary Disease~* Past or current diagnosis, signs or symptoms of significant neurological disease, in-incl. but not limited to:~* Blood clot in brain~* Stroke~* Clinically significant head trauma within the last year~* Peripheral neuropathy~* Epilepsy or seizures~* Impaired balance~* Alcohol or drug abuse within the past 5 years~* Past or current diagnosis, signs or symptoms of major psychiatric disorder~* Regional pain syndromes like fibromyalgia~* Regional pain caused by lumbar nerve root or cervical radiculopathy with or at risk for developing it

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Control (Type: NO_INTERVENTION): No intervention for 12 weeks
- Knee muscle strengthening exercises (Type: ACTIVE_COMPARATOR): None
- Upper extremity strengthening exercises (Type: ACTIVE_COMPARATOR): None
- Cardiovascular fitness exercises (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues